Cytori
Therapeutics CYTX has received Investigational Device
Exemption (IDE) approval from the FDA to begin a prospective clinical
trial to evaluate the safety and feasibility of Cytori Cell Therapy as a
potential treatment for hamstring injuries. The trial, referred to as
RECOVER, will begin as a ten-patient, open label study in 2014.
Following a 90-day assessment of the first ten patients, Cytori is
approved by the FDA to expand RECOVER to a multi-dose, multi-center,
double-blind, placebo-controlled trial. Cytori Cell Therapy is derived
from the Company's Celution® System, which enables access to a patient's
own adipose-derived regenerative cells (ADRCs) at the point-of-care.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in